The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial
ARRIVE试验:在接受抗肿瘤坏死因子治疗后停药或直接换用阿巴西普治疗的类风湿性关节炎患者中,阿巴西普6个月的安全性和有效性评估
期刊:Annals of the Rheumatic Diseases
影响因子:20.6
doi:10.1136/ard.2008.099218
Schiff, M; Pritchard, C; Huffstutter, J E; Rodriguez-Valverde, V; Durez, P; Zhou, X; Li, T; Bahrt, K; Kelly, S; Le Bars, M; Genovese, M C